To Cancer Treatment
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
CGT is led by an experienced team of biotechnology researchers and executives with proven track records in the creation, development and successful market introduction of biotechnology therapeutic products.
Denise Harrison, Chief Executive Officer
Thomas P. Hopp, PhD, Vice President, Research and Development
Gordon Duncan, PhD, Chief Clinical Officer
Stephan Karr, PhD, Director, Manufacturing & Quality Assurance
Denise Harrison, Chief Executive Officer, President, Board Member
Denise has 15 years experience in finance. She was CFO, Director of Finance and Human Resources for Illumigen Biosciences, Inc. from their inception in 2000 to 2007. At Illumigen, she oversaw all phases of corporate finance and development from startup to successful project completion and corporate acquisition by Cubist Pharmaceuticals. Denise has extensive experience in public, private and government accounting. She served as senior auditor for Deloitte and Touché and the IRS. Denise earned a Post-baccalaureate Certificate in Accountancy, Arizona State University and Bachelor of Science, Oregon State University.
Thomas P. Hopp, PhD, Vice President, Research and Development
Tom is an internationally recognized expert in immunotherapeutic research and development, a respected protein structure theorist and an inventor on patents covering vaccines, immuno-stimulating hormones, and antibodies. His discovery of two Interleukin-1 genes at Immunex Corporation was a key breakthrough for that company’s success, bringing them corporate investors and setting them on the path to their major arthritis product, ENBREL.
Prior to joining CG Therapeutics, Tom held a senior position at Corus Pharmaceuticals and was Chief Scientific Officer at ImmunoTherapy Corp. He was an Associate Member of the Torrey Pines Institute for Molecular Studies in San Diego and consulted with Houghten Pharmaceuticals Inc., to help create their product development plan. He also served as Director of Technical Development for Multiple Peptide Systems, establishing large-scale production methods for polypeptide combinatorial libraries. Prior to that, he was President of Protein Research Laboratories, Inc. and Vice President of New Research Evaluation for Immunex Corporation. Tom earned his B.S. in Molecular Biology from the University of Washington and a Ph.D. in Biochemistry from Cornell University Medical College. He completed post-doctoral training with two Nobel laureates at Rockefeller University, studying protein chemistry with Dr. G. M. Edelman and peptide chemistry with Dr. R. B. Merrifield.
Gordon Duncan, PhD, Chief Clinical Officer
Gordon has a distinguished 40-year career with major U.S. pharmaceutical companies and a principal international non-profit research and development institution. He has conducted fundamental research and managed multidisciplinary, multinational research and development programs, including a 2,000-member, three-continent research and development program. Gordon oversaw the discovery, development and launch of medically unique drugs and devices, designed and managed clinical trials and regulatory applications, and consulted for programs with government, academic and industrial institutions.
Gordon spent 20 years with the Upjohn Company as a Vice President and Executive Director. His duties included major roles in Upjohn’s drug discovery, drug development and clinical development efforts. He has more recently been a member of senior management for four emerging biopharmaceutical companies including ProCyte Corp., BioFrontiers, Inc., AVI BioPharma, and Women’s Capital Corp., where he successfully developed and launched Plan B, a significant product for women’s health care. Gordon was also the first Executive Director of PATH, an influential non-profit organization. He earned his B.S. at Cornell University and his M.S. and Ph.D. at Iowa State University.
Stephan Karr, PhD, Director, Manufacturing & Quality Assurance
Dr. Karr has more than 20 years’ experience in protein vaccine development and manufacturing. He has overseen externally-contracted product development and manufacturing programs, including process and quality management, training, and quality-related strategic planning. He also has experience with FDA and international regulations affecting biopharmaceutical approvals.
Steve spent 11 years as Director of Quality Assurance for Aphton Corporation, directing quality programs and managing contract manufacturers. Aphton was a clinical biopharmaceutical company developing targeted immunotherapies for cancer. Prior to that, he served in laboratory, research and project management positions for Aphton. Steve has a B.A. from California State University, an M.S. from the University of North Carolina and a Ph.D. in Entomology from the University of California at Davis.
